XenoTech Achieves Record Revenue and Employment Numbers
Kansas City, KS – XenoTech will celebrate its 25th anniversary this November, coming into the year with record-breaking achievements. Expansions reflect growth in the fiscal year, which ended March 31, 2019, resulting in the highest headcount in company history with new hires in many departments across the organization.
Emphasis on growth and development has been key for XenoTech and its headcount has reached an all-time high. New additions increased operational capacity and the volume of projects that can be completed in parallel to provide drug developers with products and services to meet regulatory requirements for a drug candidate prior to market entry. During this growth, it was critical to maintain both the integrity of studies and the ability to meet the scientific demands and timeline expectations of clients. This investment resulted in a total year-over-year growth of 18.9% for contract research service revenue.
Outperforming forecasts for the year, revenue and profitability have been some of the highest on record for XenoTech; in fact, the 2018 financial year saw the highest revenue achieved yet. The company has established a strong foothold and reputation with its clients and partners for unparalleled expertise and dedication to customer service, consistently reaping success as a result. Retention rate is a particular point of pride for the company; 75% of total bookings were with clients who have previous experience working with XenoTech.
New positions were added and leadership was strategically organized to meet needs and expand capabilities in speed and study capacity; areas including Lab Automation and Metrics as well as Technical Writing saw significant personnel increases and the marketing department tripled in size over the course of the financial year.
In addition to laboratory scientists and support teams, XenoTech established a Scientific Advisory Board in December of 2018. This board provides insight and voice from leading industry experts to help the company plan future endeavors and develop new products and services of superior utility to clients. The Board members were each carefully selected for superior expertise and serve to provide invaluable perspective to help guide XenoTech and provide access to premier consultants.
As the company looks to the future, leadership places a strong emphasis on efficiency and maintaining superior customer service. “People are at the core of XenoTech,” says Chief Operating Officer, Dr. Darren Warren. “It is important that we maintain and foster personal connections across our staff to better enable us to grow while providing the quality, insight and customer service that our customers have come to expect from our organization.”
For more information about XenoTech, please contact us using the information below.
About XenoTech
XenoTech, LLC is a global Contract Research Organization with unparalleled ADME/DMPK/Drug-Drug Interactions experience utilized by 98% of top pharma companies and numerous other organizations. For the past 25 years, the company has offered proven drug development expertise in evaluating drug candidates in compliance with regulatory requirement and guidance prior to entrance to market. The company offers a variety of in vitro and in vivo safety assessment studies for drug candidate evaluation, as well as an extensive selection of products for drug metabolism and pharmacokinetic research. For additional information, please refer to the company’s website at www.xenotech.com or call (913) 438-7450.